Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Chronic Kidney Disease
NCT02342639Phase 4Completed
- Start
- Jun 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic kidney disease (CKD) comparing Rifaximin with Placebo (2 arms). Primary endpoint: Change in Serum Trimethylamine N-oxide at Day 11. Started Jun 2015; status: completed.
02
Drugs
rifaximin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02342639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342639.